Pepromene Bio, Inc.
Clinical trials sponsored by Pepromene Bio, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental CAR t therapy targets tough leukemia in first human trial Results expected Nov 2026 (estimated)
- New CAR t therapy targets tough lymphoma Results expected Jul 2027 (estimated)